About us
tBrexa Bio Inc.
At tBrexa Bio, we are dedicated to transforming the landscape of biopharmaceutical manufacturing. As a Contract Development and Manufacturing Organization (CDMO), our focus is on advancing gene therapies, biologics, and large molecules for rare and unmet medical needs. We specialize in providing innovative and scalable solutions for the development and manufacturing of complex therapies, from pre-clinical stages through to commercial-scale production.
Our mission is to bridge the gap between groundbreaking scientific research and patient access. We offer end-to-end manufacturing services, ensuring our clients receive high-quality, compliant, and cost-effective solutions that accelerate the delivery of life-changing treatments to patients worldwide.
With cutting-edge infrastructure, including modular cleanrooms, single-use bioreactors, and AI-driven process analytics, we empower innovators to bring their products to market more efficiently. We are committed to providing flexibility, agility, and expertise, which allow our partners to scale quickly and meet the growing demands of the biopharma industry.
At tBrexa Bio, we take pride in fostering a culture of innovation, collaboration, and excellence, ensuring that we are at the forefront of biopharmaceutical manufacturing solutions.
Monoclonal Antibody Manufacturing
01
At tBrexa Bio, we specialize in the development and manufacturing of monoclonal antibodies (mAbs), which are at the forefront of therapeutic treatments for various diseases. As part of our commitment to innovation, we offer comprehensive CDMO services that cover all stages of monoclonal antibody production, from early-stage development through clinical and commercial manufacturing.
Our facility is equipped with advanced bioprocessing technology designed to ensure high-quality, scalable production of mAbs. With a focus on consistency and regulatory compliance, we leverage our expertise in cell line development, protein expression, purification, and formulation to provide a reliable pathway to bringing monoclonal antibody therapies to market.
Have a project in mind? Let’s get to work.
Whether you’re advancing a novel biologic or seeking a nimble CDMO partner, we’d love to hear from you. Our team responds to all inquiries within 1–2 business days.